Adjuvant therapy for melanoma: How should we respond to high-dose interferon?

British Journal of Cancer

Volumn 77, Issue 8, 1998, Pages 1287-1293

  De Takats, P G ^a   Williams, M V ^a   Hawkins, R ^b  

^a CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

Author keywords

Adjuvant interferon; Melanoma

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; DACARBAZINE; GAMMA INTERFERON; INTERFERON;

ABDOMINAL PAIN; ADJUVANT CHEMOTHERAPY; ALOPECIA; ANEMIA; ANOREXIA; CANCER SURVIVAL; CLINICAL TRIAL; CONFUSION; DEPRESSION; DIARRHEA; FATIGUE; FEVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; JAUNDICE; LEUKOENCEPHALOPATHY; LIVER FAILURE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MELANOMA; META ANALYSIS; MYALGIA; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; RETINOPATHY; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; TASTE DISORDER; VERTIGO; VOMITING;

EID: 0031909884     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.215     Document Type: Review

References (45)

1. Bajetta E, Di Leo A, Zampino MG, Sertoli MR, Comella G, Barduagni M, Giannotti B, Queirolo P, Tribbia G, Bernengo MG, Menichetti ET, Palmeri S, Russo A, Cristofolini M, Erbazzi A, Fowst C, Criscuolo D, Bufalino R, Zilembo N and Cascinelli N (1994) Multicentre randomized trial of dacarbazine alone or in combination with two different schedules of interferon alfa-2a in the treatment of advanced melanoma. J Clin Oncol 12: 806-811
2. Balch CM, Houghton AN and Peters LJ (1993) Cutaneous melanoma. In Cancer: Principles and Practice of Oncology. De Vita VT. Hellman S and Rosenberg SA. (eds). pp. 1612-1661. JB Lippincott: Philadelphia
3. Balch CM, Reintgen DS, Kirkwood JM, Houghton A, Peter L and Ang KK (1997) Cutaneous melanoma. In Cancer: Principles and Practice of Oncology. De Vita VT. Hellman S and Rosenberg SA. (eds) pp. 1947-1994. Lippineott-Raven Publishers: Philadelphia
4. Bleehan NM, Newlands ES, Lee SM, Thatcher N, Selby P, Calvert AH. Rustin GJS. Brampton M and Stevens MFG (1995) Cancer Research Campaign phase II trial of temozolamide in metastatic melanoma. J Clin Oncol 13: 910-913
5. Brossart P, Schmier J, Kruger S, Willhauck M, Scheibenbogen C. Mohler T and Keilholz U (1995) A polymerase chain reaction-based semiquantitative assessment of malignant melanoma cells in peripheral blood. Cancer Res 55: 4065-4068
6. Cascinelli N (1995) Evaluation of efficacy of adjuvant rIFNα 2a in melanoma patients with regional node metastases (abstract). Proc Am Soc Clin Oncol 14: 410
7. Cascinclli N, Bufalino R, Morabito A and Mackie R (1994) Results of adjuvant interferon study in WHO melanoma programme (letter). Lancet 343: 913-914
8. Coales A, Rallings M, Hersey P and Swanson C (1986) Phase II study of recombinant alpha 2-interferon in advanced malignant melanoma. J Interferon Res 16: 1-4
9. Cole BF, Gelber RD, Kirkwood JM, Goldhirsch A, Barylak E and Borden E (1996) Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 14: 2666-2673
10. Creagan ET, Ahmann DL, Green SJ, Long HJ, Rubin J, Schutt AJ and Dziewanowski ZE (1984) Phase II study of low-dose recombinant leukocyte A interferon (rIFN-alpha A) in disseminated malignant melanoma. Cancer 54: 2844-2849
11. Creagan ET, Loprinzi CL, Ahmann DL and Schaid DJ (1988) A phase I-II trial of the combination of recombinant leukocyte A interferon and recombinant human interferon-gamma in patients with metastatic malignant melanoma. Cancer 62: 2472-2474
12. Creagan ET, Dalton RJ, Ahmann DL, Jung S-H, Morton RF, Langdon RM, Kugler J and Rodrigue LJ (1995) Randomized, surgical adjuvant trial of recombinant interferon-alfa-2a in selected patients with malignant melanoma. J Clin Oncol 13: 2776-2783
13. Dorval T, Palangie T, Jouve M, Garcia-Giralt E, Israel L, Falcoff L, Schwab D and Pouillart P (1986) Clinical phase II trial of recombinant DNA interferon (interferon alfa 2b) in patients with metastatic malignant melanoma. Cancer 58: 215-218
14. Elsasser-Beile U and Drews H (1987) Interferon in the treatment of malignant melanoma: results of clinical studies. Fortschr Med 105: 401-403
15. Falkson CI, Falkson G and Falkson H (1991) Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncol 9: 1403-1408
16. Falkson CI, Ibrahim J, Kirkwood J and Blum R (1996) A randomized phase III trial of dacarbazine (DTIC) versus DTIC + Interferon alfa 2b (rIFN) versus DTIC + tamoxifen (TMX) versus DTIC + rlFN + TMX in metastatic malignant melanoma: and ECOG trial (abstract). Proc Am Soc Clin Oncol 15: 435
17. Fisher RI, Terry WD, Hodes RJ, Rosenberg SA, Makuch R, Gordon HG and Fisher SG (1981) Adjuvant immunotherapy or chemotherapy for malignant melanoma: preliminary report of the National Cancer Institute randomized clinical trial. Surg Clin North Am 61: 1267-1277
18. Groh JJ, Dreno B, Delaunay M, Chastang C, Guillot B, Cupissol B, Souteyrand P, Sassolas B, Cesarini JP, Thivolet J, Denocux JP, Ortanne JP, Thomas L, Beylot C, Truchetet F, Lovette G, Chemaly C, Meynadier J, Amblard P, Thyss P, Avril MF, Prigent F and Bonerandi JJ (1996) Results of the French multicentre trial on adjuvant therapy with interferon alfa-2a in resected primary melanoma (> 1.5 mm) (abstract). Proc Am Soc Clin Oncol 15: 437
19. Hersey P, Hasic E, Macdonald M, Edwards A, Spurling A, Coates AS, Milton GW and McCarthy WH (1985) Effects of recombinant leukocyte interferon (rIFN-alpha A) on tumour growth and immune responses in patients with metastatic melanoma. Br J Cancer 51: 815-826
20. Hillner BE, Kirkwood JM, Atkins MB, Johnson FR and Smith TJ (1997) Economic analysis of adjuvant interferon-alfa 2b in high risk melanoma based on projections from Elastern Cooperative Oncology Group 1684. J Clin Oncol 15: 2351-2358
21. Kaiser LR, Burk MW and Morton DI (1981) Adjuvant therapy tor malignant melanoma. Surg Clin North Am 61: 1249-1257
22. Kerin MJ, Gillen P, Monson JR, Wilkie J, Keane FB and Tanner WA (1995) Results of a prospective randomized trial using DTIC and interferon as adjuvant therapy for stage 1 malignant melanoma. Eur J Surg Oncol 21: 548-550
23. Kirkwood JM, Ernstoff MS, Davis CA, Reiss M, Ferraresi R and Rudnick SA (1985) Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers. Ann Intern Med 103: 32-36
24. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC and Blum RH (1996) Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14: 7-17
25. Legha SS (1997) The role of interferon alfa in the treatment of metastatic melanoma. Sein Oncol 24: 24-31
26. Legha SS, Papadopoulos NE, Plager C, Ring S, Chawla SP, Evans LM and Benjamin RS (1987) Clinical evaluation of recombinant interferon alfa-2a (Roferon-A) in metastatic melanoma using two different schedules. J Clin Oncol 5: 1240-1246
27. Livingstone PO, Wong GYC, Adluri S, Tao Y, Padavan M, Parente R, Hanlon C, Calves MJ, Helling F, Ritter G, Oettgen HF and Old LJ (1994) Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 12: 1036-1044
28. McClay EF and McClay M-ET (1996) Systemic chemotherapy for the treatment of metastatic melanoma. Sem Oncol 23: 744-753
29. Meisenberg BR, Ross M, Vredenburgh JJ, Jones R, Shpall FJ, Seigler HF, Coniglio DM, Wu K and Peters WP (1993) Randomized trial of high-dose chemotherapy with autologous bone marrow support as adjuvant therapy for high-risk, multinode positive malignant melanoma. J Natl Cancer Inst 85: 1080- 1085
30. Meyskens FL Jr, Kopecky K, Samson M, Hersh E, Macdonald J, Jaffe H, Crowley J and Coltman C (1990) Recombinant human interferon-γ: adverse effects in high-risk stage I and II cutaneous malignant melanoma (letter). J Natl Cancer Inst 82: 1071
31. Meyskens FL, Liu P, Tuthill RJ, Sondak VK, Fletcher WS and Jewell WR (1994) Randomized trial of vitamin A versus observation as adjuvant therapy in high-risk primary malignant melanoma: a Southwest Oncology Group study. J Clin Oncol 12: 2060-2065
32. Meyskens FL Jr, Kopecky KJ, Taylor CW, Noyes RD, Tuthill RJ, Hersh EM, Feun IG, Doroshow JH, Flaherty LE and Sondak VK (1995) Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study. J Natl Cancer Inst 87: 1710-1713
33. Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, Foshag LJ and Cochran AJ (1992) Technical details of intraoperative lympathic mapping for early-stage melanoma. Arch Surg 127: 392-399
34. Office of Population Censuses and Surveys (1994) Cancer statistics: registrations of cancer diagnosed in 1988, England and Wales. HMSO: London
35. Parkinson DR (1991) Levamisole as adjuvant therapy for melanoma: quo vadis? J Clin Oncol 9: 2052
36. Robinson WA, Mughal TI, Thomas MR, Johnson M and Spiegel RJ (1986) Treatment of metastatic malignant melanoma with recombinant interferon alpha 2. Immunobiology 172: 275-282
37. Sertoli MR, Bernengo MG, Ardizzoni A, Brunetti I, Falcone A, Vidili MG, Cusimano MP, Appino A, Doveil G and Fortini C (1989) Phase II trial of recombinant alpha-2b interferon in the treatment of metastatic skin melanoma. Oncology 46: 96-98
38. Smith B, Selby P, Southgate J, Pitman K, Bradley C and Blair GE (1991) Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 388: 1227-1229
39. Spitler LE (1991) A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma. J Clin Oncol 9: 736-740
40. Steiner A, Wolf C and Pehamberger H (1987) Comparison of the effects of three different treatment regimens of recombinant interferons (rlFN alpha, rIFN gamma and rIFN alpha + cimetidine) in disseminated malignant melanoma. J Cancer Res Clin Oncol 113: 459-465
41. Tan JK and Ho VC (1993) Pooled analysis of the efficacy of bacille Calmette-Guerin (BCG) immunotherapy in malignant melanoma. J Dermatol Surg Oncol 19: 985-990
42. Thomson DB, Adena M, McCleod GR, Hersey P, Gill PG, Coates AS, Olver In, Kefford RF and Lowenthal RM (1993) Interferon alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial. Melanoma Res 3: 133-138
43. Veronesi U, Adamus J, Aubert C, Bajetta E, Beretta G, Bonadonna G, Bufalino R, Cascinelli N, Cocconi G, Durand J, De Marsillac J, Ikonopisov RL, Kiss B, Lejeune F, Mackie R, Madej G, Mulder H, Mechl Z, Milton GW, Morabito A, Peter H, Priario J, Paul E, Rumke P, Sertoli R and Tomin R (1982) A randomised trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. New Engl J Med 307: 913-916
44. Wang X, Heller R, Vanvoorhis N, Cruse CW, Glass F, Fenske N, Berman C, Leo-Messina J, Rappaport D and Wells K (1994) Detection of submicroscopic metastases with polymerase chain reaction in patients with malignant melanoma. Ann Surg 220: 768-774
45. Williams MV, de Takats PG and Parmer M (1997) Survival benefit in melanoma. J Clin Oncol 15: 2172